Does alemtuzumab improve relapse rate and EDSS in patients with multiple sclerosis?
In a real-world Danish cohort, alemtuzumab maintained relapse rate reduction and stabilized or improved EDSS over 5 years without novel serious adverse events.
In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed.
Theódórsdóttir et al. (Mon,) studied this question.